Introduction
SPARK計畫2006年發源於美國史丹福大學，由Prof. Daria Mochly-Rosen創立，主要目標是幫助大學內的學研成果轉譯成為造福病患與社會的商品，計畫執行已超過16年，達到成功率超過6成的驚人成績，並持續將其成功經驗分享至全球各地；目前已有超過20個國家引進或即將導入SPARK計畫，SPARK Global組織也在經歷多次跨國討論會議後逐漸成形，目標匯聚Translational Scientists without Borders，聯合全球學術界和產業界專家，通過教育和計畫支持讓學術界之發現和創新解決方案更有效率轉譯為產業所用，從而改善人類健康。
SPARK Taiwan作為第一個海外SPARK計畫的執行國家，今年執行已邁入第10年累積輔導超過300個我國生醫學研團隊商品化，同時也致力協助其他國家的SPARK計畫執行，包括於台灣生技月舉辦SPARK Asia Showcase等跨國合作活動與經驗分享。
When life gives you lemons, make lemonade!「當生活給了你酸溜溜的檸檬時，就把它做成酸酸甜甜的檸檬汁吧!」這是一句英語諺語，用來比喻將各種不利的狀況轉為機運並盡力而為的態度，而這正是創業家的日常! 今年，我們很榮幸邀請到Stanford SPARK 創始人、SPARK Global 創始人之一的 Daria Mochly-Rosen 教授分享她將失敗轉化為激動人心的新機遇和成功的寶貴創業經驗。您想知道 Biodesign 和 SPARK 如何共同幫助患者嗎？我們有幸邀請史丹福大學Biodesign Director、Tarsus Pharmaceuticals（納斯達克股票代碼：TARS）董事長Dr. Michael Ackermann介紹Biodesign流程應用於健康科技之創新開發。此外，我們還邀請到兩位專家，Stanford SPARK共同領導人Prof. Kevin Grimes 與計劃經理Dr. Jeewon Kim分享臨床試驗之設計和介紹美國生命科學市場。熱烈歡迎SPARK團隊和對轉譯醫學領域感興趣的人士參加SPARK Symposium。
因應疫情SPARK Symposium採線上舉辦，感謝各國SPARK業師的熱情支持與分享，期待各位的線上參與!
The SPARK Program founded by Professor Daria Mochly-Rosen in 2006 at Stanford University in USA. The main goal of this program is to translate the academic discoveries in the university into products that benefit patients and society. This program has been implemented for more than 16 years and has achieved an amazing success rate of over 60%. Its successful experience is shared all over the world. At present, more than 20 countries have introduced or are about to introduce the SPARK Program, and SPARK Global is gradually taking shape after multiple transnational meetings. The goal is to gather Translational Scientists without Borders, to improve human health by uniting academics and industry experts around the globe to generate an efficient, effective and exciting pathway for translation of academic discoveries and innovative solutions through education and project support.
SPARK Taiwan, as the first country where the SPARK Program is implemented overseas, has entered the tenth year of implementation and has helped over 300 biomedical research teams in the country with commercialization. At the same time, it is also committed to assisting the implementation of SPARK projects in other countries, including holding SPARK Asia Showcase and other multinational cooperation activities and experience sharing in Taiwan Biotechnology Month.
When life gives you lemons, make lemonade! That’s exactly what entrepreneurs do. This year, it is honored to invite Prof. Daria Mochly-Rosen, the founder of Stanford SPARK and one of the founders of SPARK Global, to share her invaluable entrepreneurial experience in turning a failure into exciting new opportunities and a success. Have you wonder how Biodesign and SPARK work together to help patients? It is privileged to invite Dr. Michael Ackermann, the director of Biotechnology for the Stanford University Byers Center for Biodesign and Chairman of the Board of Tarsus Pharmaceuticals (NASDAQ: TARS) to introduce Biodesign process for health technology innovation. In addition, two of Stanford SPARK practitioners, the co-director Prof. Kevin Grimes and the program manager Dr. Jeewon Kim were invited to share on clinical trial design and the US Life science market introduction. New SPARK teams and those who are interested in the field of biomedical translation are welcomed to participate in the SPARK Symposium.
Due to the epidemic, SPARK Symposium will be held online. Thanks to SPARK professionals from all over the world for their enthusiastic support and sharing. We look forward to your participation online.
Date/Time:
[Taiwan Time] 2022/10/31(Mon) 09:00 AM ~12:35 PM
[SFO Time] 2022/10/30(Sun) 06:00 PM ~ 09:35 PM
Venue:
Online** The video URL will be notified by email 2 days before the symposium.
Organizer:
SPARK Taiwan Office, Science & Technology Policy Research and Information Center, National Applied Research Laboratories
Contact info:
sparktw@narlabs.org.tw (SPARK Taiwan Office)
Advisor 指導單位
Organizer 主辦單位
Agenda
Date:
2022/10/31(Mon) 09:00 AM ~12:35 PM (Taiwan time);
2022/10/30(Sun) 06:00 PM ~ 09:35 PM(PDT)
Venue: ON-LINE
| Taiwan Time (SFO Time) |
Topics | Speakers |
|---|---|---|
| 09:00 ~ 9:30 AM (6:00 ~ 6:30 PM) |
Registration |
|
| 09:30 ~ 9:40 AM (6:30 ~ 6:40 PM) |
Opening Remarks |
Prof. Y. Jane Tseng Director, SPARK Taiwan Program |
| 9:40 ~ 10:20 AM (6:40 ~ 7:20 PM) |
Keynote Session-I How to Make Lemonade from Lemons; Turning a Failure Into a Success |
Prof. Daria Mochly-Rosen Founder and co-Director of SPARK At Stanford, |
| 10:20 ~ 11:00 AM (7:20 ~ 8:00 PM) |
Keynote Session-II Biodesign Process for Health Technology Innovation |
Dr. Michael Ackermann Director of Biotechnology for the Stanford |
| 11:00 ~ 11:10 AM (8:00 ~ 8:10 PM) |
Break |
|
| 11:10 ~ 11:50 AM (8:10 ~ 8:50 PM) |
Session I Clinical Trial Design |
Prof. Kevin Grimes Co-Director of SPARK At Stanford |
| 11:50 AM ~ 12:30 PM (8:50 ~ 9:30 PM) |
Session II A Brief Introduction to the US Life Science Market |
Dr. Jeewon Kim Program manager of SPARK At Stanford |
| 12:30 ~12:35 PM (9:30 ~9:35 PM) |
Closing Remarks |
Prof. Y. Jane Tseng Director, SPARK Taiwan Program |
Speakers
Prof. Daria Mochly-Rosen
Founder and Director of SPARK At Stanford,
Professor of Chemical and Systems Biology, Stanford University School of Medicine
Professor Daria Mochly-Rosen helps academics navigate the so-called “valley of death” between drug discovery and development. Professor Mochly-Rosen founded The SPARK Program at Stanford in 2006 after having to leave academia to start a pharmaceutical company to translate her protein kinase C research into cardiovascular therapeutics. Challenging the academic dogma of how scientific discoveries should reach the pharmaceutical industry, the SPARK model has been implemented internationally and has resulted in a book about drug development from academia. Professor of Chemical and Systems Biology at Stanford, she leads a multi-disciplinary research lab that includes chemists, biochemists, biologists and physician scientists. She has published over 285 papers and over 36 patents and patent applications. Professor Mochly-Rosen is originally from Israel, where she received her doctorate in Chemical Immunology from The Weizmann Institute of Science.
Dr. Michael Ackermann
Director of Biotechnology for the Stanford
University Byers Center for Biodesign,.
Co-founder and Chairman of Tarsus Pharmaceuticals
Michael is Director of Biotechnology for the Stanford University Byers Center for Biodesign. He is also co-founder and serves as Chairman of the Board of Tarsus Pharmaceuticals (NASDAQ: TARS). Michael is also co-founder, former CEO, and serves on the board of Presidio Medical. Previously, he was co-founder and served as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST). Prior to this, he was Vice President, Neurostimulation for Allergan (an AbbVie company), after serving as co-founder and CEO of Oculeve, Inc., which was acquired by Allergan, plc. Michael received a BE degree from Vanderbilt University and MS and PhD degrees from Case Western Reserve University. He is a graduate of the Stanford University Biodesign Fellowship and Vision Research Fellowship. He has more than 50 issued US patents and numerous patent applications and peer-reviewed publications.
Prof. Kevin Grimes
Co-Director of SPARK At Stanford
Professor of Chemical and Systems Biology,
Stanford University School of Medicine
Kevin Grimes, MD is Professor of Chemical and Systems Biology and Co-director of the SPARK Program at Stanford. While a Clinical Assistant Professor of Medicine at Stanford, he obtained an MBA at the Stanford Graduate School of Business. He was selected as a White House Fellow and served as Special Assistant to the Secretary of Defense. After 15 years in the biotech industry, he returned to Stanford. SPARK’s mission is to advance promising discoveries to patient care; to educate faculty and trainees regarding the translational process; and to identify more efficient approaches to bring new therapies to patients. The SPARK methodology has been adopted by over 50 academic institutions world-wide. Grimes teaches graduate student courses on drug discovery and development and continues to teach and practice internal medicine. He received the David Rytand Award for Excellence in Clinical Teaching and the Faculty Award for Excellence in Graduate Teaching.
Dr. Jeewon Kim
Program manager of SPARK At Stanford
Jeewon Kim received her undergraduate degree at Seoul National University in Korea and worked at Daesang Ltd, a Food and Drug company in Korea. She did her doctoral work at UC Berkeley in the lab of Dr. Marc Hellerstein, where she developed a stable isotope biomarker to detect early phases of colon cancer. She subsequently worked as a consultant for startup company Kinemed Inc. Then as a postdoctoral fellow, she began drug development work in Dr. Daria Mochly-Rosen’s lab at Stanford, studying the roles of different protein kinase C (PKC) isozymes in breast and prostate cancer. While in Dr. Mochly-Rosen’s lab, she worked to develop small peptides as anticancer drugs. This work has resulted in multiple publications and review papers and identified the roles of PKCs in cancer proliferation, angiogenesis, migration and metastasis. She then worked at the Stanford Cancer Institute Transgenic, Knockout and Tumor model Center (TKTC) as a group lead and preclinical oncology facility manager. She is currently a program manager and associate director of business development at SPARK since 2019.
SPARK Taiwan 計畫辦公室
羅庭芳 專案經理 | 02-2737-7833 | sparktw@narlabs.org.tw
Copyright © SPARK TAIWAN. All rights reserved.